Health-related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study Academic Article uri icon

Overview

MeSH Major

  • Heparin
  • Thrombocytopenia

abstract

  • The PETIT (Eltrombopag in Pediatric Patients with Thrombocytopenia from Chronic ITP) trial showed that in children aged 1-17¬†years with chronic or persistent immune thrombocytopenia (ITP), eltrombopag improved platelet counts, decreased clinically significant bleeding and reduced rescue medication need. We report the health-related quality of life (HRQoL) results from the PETIT study using the Kids' ITP Tools (KIT). A limitation was that PETIT was not powered for the HRQoL analysis. Eltrombopag did not impact children's HRQoL assessed by the KIT. Although median KIT scores in children treated with eltrombopag with platelet responses were numerically higher compared with non-responders in some age groups, the interquartile ranges overlapped.

publication date

  • April 2019

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1111/bjh.15732

PubMed ID

  • 30592022

Additional Document Info

start page

  • 102

end page

  • 106

volume

  • 185

number

  • 1